memantine

Ebixa (CA) (UK), Namenda

Pharmacologic class: N-methyl-D-aspartate receptor antagonist (NMDA)

Therapeutic class: Anti-Alzheimer's agent

Pregnancy risk category B

Action

Unclear. Thought to act as a low- to moderate-affinity NMDA receptor antagonist, binding to NMDA receptor-operated channels. (Activation of these channels is thought to contribute to Alzheimer's symptoms.)

Availability

Oral solution: 2 mg/ml

Tablets: 5 mg, 10 mg

Tablets (titration pack): 28 tablets of 5 mg and 21 tablets of 10 mg

Indications and dosages

➣ Moderate to severe Alzheimer's-type dementia

Adults: Initially, 5 mg P.O. daily. Then titrate at intervals of at least 1 week in 5-mg increments, to a maximum of 10 mg P.O. b.i.d.

Dosage adjustment

• Moderate renal impairment

Contraindications

• Hypersensitivity to drug or its components

Precautions

Use cautiously in:

• neurologic conditions, moderate to severe renal impairment, genitourinary conditions that increase pH

• pregnant or breastfeeding patients.

Administration

• Give with or without food.

Adverse reactions

CNS: dizziness, headache, syncope, aggressive reaction, confusion, somnolence, hallucinations, agitation, insomnia, vertigo, ataxia, abnormal gait, hypokinesia, anxiety, transient ischemic attack, cerebrovascular accident (CVA)

CV: hypertension, cardiac failure

EENT: cataract, conjunctivitis

GI: nausea, vomiting, diarrhea, constipation, anorexia

GU: frequent voiding, urinary incontinence, urinary tract infection

Hematologic: anemia

Musculoskeletal: back pain, arthralgia

Respiratory: cough, dyspnea, bronchitis, pneumonia

Skin: rash

Other: weight loss, fatigue, pain, falls, flulike symptoms, peripheral edema

Interactions

Drug-drug. Cimetidine, hydrochlorothiazide, nicotine, quinidine, ranitidine, triamterene: altered blood levels of both drugs

Urine-alkalizing drugs (carbonic anhydrase inhibitors, sodium bicarbonate): decreased memantine elimination

Drug-diagnostic tests. Alkaline phosphatase: increased level

Patient monitoring

See Check for heart failure and signs and symptoms of CVA.

• Monitor kidney function tests.

Patient teaching

• Tell patient to take with or without food.

• Instruct patient or caregiver not to mix solution with other liquids and to take or give oral solution only with included dosing device.

• Make sure patient or caregiver understands dose escalation.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

memantine

(mə-măn′tēn)n. A drug, C₂₀H₂₄N₅O₄, used in its hydrochloride form to treat symptoms of Alzheimer's disease by inhibiting NMDA receptors.

memantine

An NMDA (N-methyl D-aspartate) receptor antagonist that counters the toxic effects of glutamate excess to manage the symptoms of moderate to severe Alzheimer’s disease.
Adverse effects
Hallucinations, confusion, dizziness, headache, hypertonia, nausea, vomiting, constipation, hypertonia, cystitis, increased libido.

Proposed mechanism
Interferes with homocysteine binding at the NMDA receptor; homocysteine also mediates excitotoxicity, and disturbs glutamatergic neurotransmission.

memantine

An inhibitor of glutamate NMDA RECEPTORS used with the expectation of delaying the progress of ALZHEIMER'S DISEASE and other forms of dementia. It has been shown to have some value even in the later stages of dementia. A brand name is Ebixa.

单词	memantine
释义	memantine me·man·tine M5222500 (mə-măn′tēn)n. A drug, C₂₀H₂₄N₅O₄, used in its hydrochloride form to treat symptoms of Alzheimer's disease by inhibiting NMDA receptors. [me(thyl) + (ada)mant(ane), molecule with a diamond-like structure (from Greek adamās, adamant-, diamond; see adamant) + -ine.] Translations memantine memantine Ebixa (CA) (UK), Namenda *Pharmacologic class:* N-methyl-D-aspartate receptor antagonist (NMDA) *Therapeutic class:* Anti-Alzheimer's agent *Pregnancy risk category B* Action Unclear. Thought to act as a low- to moderate-affinity NMDA receptor antagonist, binding to NMDA receptor-operated channels. (Activation of these channels is thought to contribute to Alzheimer's symptoms.) Availability Oral solution: 2 mg/ml Tablets: 5 mg, 10 mg Tablets (titration pack): 28 tablets of 5 mg and 21 tablets of 10 mg Indications and dosages ➣ Moderate to severe Alzheimer's-type dementia Adults: Initially, 5 mg P.O. daily. Then titrate at intervals of at least 1 week in 5-mg increments, to a maximum of 10 mg P.O. b.i.d. Dosage adjustment • Moderate renal impairment Contraindications • Hypersensitivity to drug or its components Precautions Use cautiously in: • neurologic conditions, moderate to severe renal impairment, genitourinary conditions that increase pH • pregnant or breastfeeding patients. Administration • Give with or without food. Adverse reactions CNS: dizziness, headache, syncope, aggressive reaction, confusion, somnolence, hallucinations, agitation, insomnia, vertigo, ataxia, abnormal gait, hypokinesia, anxiety, transient ischemic attack, cerebrovascular accident (CVA) CV: hypertension, cardiac failure EENT: cataract, conjunctivitis GI: nausea, vomiting, diarrhea, constipation, anorexia GU: frequent voiding, urinary incontinence, urinary tract infection Hematologic: anemia Musculoskeletal: back pain, arthralgia Respiratory: cough, dyspnea, bronchitis, pneumonia Skin: rash Other: weight loss, fatigue, pain, falls, flulike symptoms, peripheral edema Interactions Drug-drug. Cimetidine, hydrochlorothiazide, nicotine, quinidine, ranitidine, triamterene: altered blood levels of both drugs Urine-alkalizing drugs (carbonic anhydrase inhibitors, sodium bicarbonate): decreased memantine elimination Drug-diagnostic tests. Alkaline phosphatase: increased level Patient monitoring See Check for heart failure and signs and symptoms of CVA. • Monitor kidney function tests. Patient teaching • Tell patient to take with or without food. • Instruct patient or caregiver not to mix solution with other liquids and to take or give oral solution only with included dosing device. • Make sure patient or caregiver understands dose escalation. • As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above. memantine (mə-măn′tēn)n. A drug, C₂₀H₂₄N₅O₄, used in its hydrochloride form to treat symptoms of Alzheimer's disease by inhibiting NMDA receptors. memantine An NMDA (N-methyl D-aspartate) receptor antagonist that counters the toxic effects of glutamate excess to manage the symptoms of moderate to severe Alzheimer’s disease. Adverse effects Hallucinations, confusion, dizziness, headache, hypertonia, nausea, vomiting, constipation, hypertonia, cystitis, increased libido. Proposed mechanism Interferes with homocysteine binding at the NMDA receptor; homocysteine also mediates excitotoxicity, and disturbs glutamatergic neurotransmission. memantine An inhibitor of glutamate NMDA RECEPTORS used with the expectation of delaying the progress of ALZHEIMER'S DISEASE and other forms of dementia. It has been shown to have some value even in the later stages of dementia. A brand name is Ebixa.
随便看	vincent willem van gogh vincent’s angina vincent’s disease vincent’s gingivitis vincent’s infection vincent’s stomatitis vincent’s tonsillitis vincenz czerny vincenz fukala vincenzo bellini vincenzo carducci vincenzo gioacchino pecci vincenzo gioberti vincenzo monti vincenzo neri vincenzo patella vincenzo ricci vincenzo russo vincenzo scamozzi vincere vinces virus vincetoxicum vincetoxicum hirsutum vincetoxicum negrum vincetoxin

memantine

me·man·tine

memantine

memantine

Action

Availability

Indications and dosages

Dosage adjustment

Contraindications

Precautions

Administration

Adverse reactions

Interactions

Patient monitoring

Patient teaching

memantine

memantine

memantine